Global & Usa Cancer Immunotherapy Market Analysis To 2020
Researchmoz added Most up-to-date research on "Global & Usa Cancer Immunotherapy Market Analysis To 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells" to its huge collection of research reports.
This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone. This report describes the evolution of such a huge market in 11 chapters supported by 114 tables and 41 figures over 256 pages.
An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies.
Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines.
Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.
Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market).
Insight into the various immunotherapeutics available for specific cancer types.
Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.
Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs.
Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs.
Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe.
Summary table to identify the category of immunotherapy drug offered by the 76 companies.
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=272900
The report is supported by 155 tables & figures over 246 pages. This report is presented as follows:
The global market for cancer immunotherapy by the following sub-categories are presented:
By Segment (Monoclonal Antibodies, Cancer Vaccines, Non-Specific Therapies, Checkpoint Inhibitors)
By Product Segment (Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT) & IDO Inhibitors
By Company (e.g Amgen, Merck, Eli Lilly, GlaxoSmithKline, Janssen, Genentech, Roche, Bristol Myers Squibb)
A comprehensive account of company product portfolios are provided for 78 Cancer Immunotherapy pharma and biotech companies including:
Amgen Inc.
Biogen Idec Inc.x
Bristol-Myers Squibb Co.
Cellectis
Cellerant Therapeutics Inc.
Celldex Therapeutics
Eli Lilly and Co.
EMD Serono Inc.
Genentech Inc.
Genmab AS
GlaxoSmithKline
ImmunoGen Inc.
Immunomedics Inc.
Janssen Biotech Inc.
Juno Therapeutics Inc.
Merck & Co., Inc.
Oxford BioTherapeutics Ltd.
Progenics Pharmaceuticals Inc.
Roche Holdings Inc.
Seattle Genetics Inc.
Sorrento Therapeutics Inc.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://latestmedicalrelatedresearchreport.blogspot.in/
This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone. This report describes the evolution of such a huge market in 11 chapters supported by 114 tables and 41 figures over 256 pages.
An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies.
Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines.
Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.
Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market).
Insight into the various immunotherapeutics available for specific cancer types.
Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.
Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs.
Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs.
Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe.
Summary table to identify the category of immunotherapy drug offered by the 76 companies.
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=272900
The report is supported by 155 tables & figures over 246 pages. This report is presented as follows:
The global market for cancer immunotherapy by the following sub-categories are presented:
By Segment (Monoclonal Antibodies, Cancer Vaccines, Non-Specific Therapies, Checkpoint Inhibitors)
By Product Segment (Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT) & IDO Inhibitors
By Company (e.g Amgen, Merck, Eli Lilly, GlaxoSmithKline, Janssen, Genentech, Roche, Bristol Myers Squibb)
A comprehensive account of company product portfolios are provided for 78 Cancer Immunotherapy pharma and biotech companies including:
Amgen Inc.
Biogen Idec Inc.x
Bristol-Myers Squibb Co.
Cellectis
Cellerant Therapeutics Inc.
Celldex Therapeutics
Eli Lilly and Co.
EMD Serono Inc.
Genentech Inc.
Genmab AS
GlaxoSmithKline
ImmunoGen Inc.
Immunomedics Inc.
Janssen Biotech Inc.
Juno Therapeutics Inc.
Merck & Co., Inc.
Oxford BioTherapeutics Ltd.
Progenics Pharmaceuticals Inc.
Roche Holdings Inc.
Seattle Genetics Inc.
Sorrento Therapeutics Inc.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://latestmedicalrelatedresearchreport.blogspot.in/
Comments
Post a Comment